Evaluation of the Regulatory Effect of the Pan-PPAR Agonist Chiglitazar on the Dawn Phenomenon
Authors:
Open Access
- 28 February 2025
- journal article
- research article
- Published by Springer Nature in Diabetes Therapy
- Vol. 16 (4) , 731-748
Abstract
Introduction The dawn phenomenon (DP), characterized by early morning hyperglycemia, poses a significant challenge in diabetes management and is associated with increased glycemic variability and long-term complications. Despite its clinical impact, effective therapeutic strategies remain limited. Chiglitazar, a novel pan-PPAR agonist, has demonstrated benefits in improving lipid metabolism and insulin sensitivity, but its potential role in mitigating DP remains unexplored. This study evaluates the regulatory effect of chiglitazar on DP and investigates its possible mechanisms beyond lipid modulation. Methods This retrospective observational study included 22 hospitalized diabetic patients who received chiglitazar (20 mg). Blood glucose levels at 3:00 a.m. and fasting glucose levels over three consecutive days were measured pre- and post-treatment, and the dawn phenomenon intensity was calculated. Lipid profiles were assessed to explore potential correlations with glucose changes. Results Following chiglitazar administration, significant reductions were observed in LDL-C (43.82 ± 18.27 vs. 36.97 ± 16.90, p < 0.05), FFA (6.00 ± 2.38 vs. 5.06 ± 1.77, p < 0.05), mean 3:00 a.m. blood glucose (Z = – 2.03, p < 0.05), and fasting blood glucose (Z = – 2.96, p < 0.05). DP intensity also significantly improved (Z = – 3.48, p < 0.01). However, no significant correlation was found between glucose improvements and lipid profile changes (p > 0.05), suggesting an alternative mechanism of action. Conclusions Chiglitazar effectively reduces DP intensity and improves glycemic control, independent of its effects on lipid metabolism. These findings suggest a potential link between chiglitazar’s mechanism and circadian rhythm regulation, possibly through the modulation of REV-ERB nuclear receptors. Further research is needed to confirm this hypothesis and evaluate the long-term clinical benefits of chiglitazar in diabetes management.Keywords
This publication has 46 references indexed in Scilit:
- Cardiovascular effects of treatment of type 2 diabetes with pioglitazone, metformin and gliclazideInternational Journal Of Clinical Practice, 2004
- The Orphan Nuclear Receptor REV-ERBα Controls Circadian Transcription within the Positive Limb of the Mammalian Circadian OscillatorCell, 2002
- Roles of PPARs in health and diseaseNature, 2000
- Occurrence of Dawn Phenomenon Without Change in Insulin Clearance in Patients With Insulin-Dependent Diabetes MellitusDiabetes, 1986
- Pathogenesis of the Dawn Phenomenon in Patients with Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1985
- The “Dawn Phenomenon” — A Common Occurrence in Both Non-Insulin-Dependent and Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1984
- Examination of the Role of the Pituitary-Adrenocortical Axis, Counterregulatory Hormones, and Insulin Clearance in Variable Nocturnal Insulin Requirements in Insulin-dependent DiabetesDiabetes, 1983
- Early-Morning Hyperglycemia in Diabetic Individuals Treated with Continuous Subcutaneous Insulin InfusionDiabetes Care, 1983
- The Dawn Phenomenon, an Early Morning Glucose Rise: Implications for Diabetic Intraday Blood Glucose VariationDiabetes Care, 1981
- Failure of Cortisol Blockade to Inhibit Early Morning Increases in Basal Insulin Requirements in Fasting Insulin-dependent DiabeticsDiabetes, 1980